Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25799309 | 1.00 | TNKS (0.40) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL25799311 | 1.00 | TNKS (0.40) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL10263669 | 0.82 | CYP3A4 (0.34) | HPGDHIF1ALMNAGABRA1GABRG2 | |
| SCHEMBL21787493 | 0.81 | TNKS (0.40) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL21787495 | 0.81 | TNKS (0.40) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL21777429 | 0.81 | TNKS (0.40) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL21777243 | 0.78 | TNKS (0.38) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL21787502 | 0.78 | TNKS (0.38) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL25799314 | 0.76 | KDM4E (0.41) | TNKSTNKS2KDM4EGAAHPGD | |
| SCHEMBL25087408 | 0.75 | TNKS (0.45) | TNKSTNKS2KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2020047207-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219949-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | TNKS 841/4885TNKS2 855/4885KDM4E 3514/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | TNKS 489/4885TNKS2 437/4885KDM4E 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.